

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Adherium Limited
<b>ABN</b>	24 605 352 510

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	George Baran
<b>Date of last notice</b>	2 December 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Issue of placement securities to Trudell Medical Limited. The Director has a 33.33% beneficial interest in Trudell Medical Limited.
<b>Date of change</b>	28 October 2022
<b>No. of securities held prior to change</b>	(a) Indirect interest in 423,080,272 fully paid ordinary shares (a) Indirect interest in 10,485,950 options over fully paid ordinary shares, each with a \$0.0219 exercise price and 29 January 2027 expiry date
<b>Class</b>	Ordinary fully paid shares and unlisted options
<b>Number acquired</b>	527,500,000 ordinary fully paid shares and 263,750,000 options over fully paid ordinary shares, each with a \$0.01 exercise price and 31 March 2024 expiry date
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$2,637,500 cash

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p>(a) Indirect interest in 950,580,272 fully paid ordinary shares</p> <p>(b) Indirect interest in 263,750,000 options over fully paid ordinary shares, each with a \$0.01 exercise price and 31 March 2024 expiry date</p> <p>(c) Indirect interest in 10,485,950 options over fully paid ordinary shares, each with a \$0.0219 exercise price and 29 January 2027 expiry date</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in placement offer

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable
---	----------------

---

+ See chapter 19 for defined terms.